SharpLink Announcement Breathes New Life Into Ether ETFs
The iShares Ethereum Trust (ETHA) saw $32 million of inflows on Tuesday as Ether prices rallied to three-month highs.
The surge came after Nasdaq-listed SharpLink Gaming Inc. (SBET) announced plans to raise $425 million to purchase Ether, with Consensys Software Inc. and other crypto-focused investors participating in the deal. Ether jumped 4% on the news, while shares of SharpLink soared 433%, closing at $35.83. That's more than five times the $6.15 per share price of the capital raise.
SharpLink's rally evoked comparisons to MicroStrategy Inc., now rebranded as Strategy Inc. (MSTR), which famously transformed itself into a de facto Bitcoin holding company in 2020.
Like Strategy, SharpLink's core business has nothing to do with crypto. It operates as a marketing partner for sportsbook and online casino gaming platforms. In 2024, the company was unprofitable and had less than $4 million in revenue. Prior to Tuesday, its market cap was only $15 million.
But crypto bulls are betting that SharpLink could play a similar role for Ether that Strategy did for Bitcoin. In 2020, Strategy's first Bitcoin purchases came when it had a market cap under $1.5 billion. Today, it's worth more than $100 billion—more than the value of the Bitcoin it holds—thanks to investors piling in and the company leveraging that enthusiasm to raise even more capital for Bitcoin buys.
It's a bold blueprint that other firms have tried to mimic, though none have yet had the same success. Still, the mere possibility of a 'Strategy for Ether' narrative has some investors intrigued. If SharpLink can spark a similar flywheel—raising money to buy Ether, fueling a stock surge, enabling more fundraising and ultimately more Ether purchases—it could become a meaningful catalyst for the second-largest cryptocurrency, which has lagged significantly behind Bitcoin this cycle.
As of Tuesday, Bitcoin was trading near $110,000, roughly 62% above its 2021 peak. Ether, meanwhile, hovered around $2,700, still 44% below its all-time high. Some of the underperformance reflects concerns about Ether's role in the smart contract space, with newer blockchains like Solana nipping at its heels.
ETF flows tell the story, too. Since the start of 2025, spot Bitcoin ETFs have attracted nearly $10 billion, while Ether ETFs have seen just $100 million in inflows. The iShares Bitcoin Trust ETF (IBIT) now has $72.4 billion in assets, compared to just $3.6 billion for ETHA.
Whether SharpLink can change that remains to be seen. But in a crypto market starved for Ether-specific catalysts, Tuesday's fireworks were more than welcome.Permalink | © Copyright 2025 etf.com. All rights reserved
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
The Best Top-Ranked Stocks to Buy in June
The S&P 500 jumped 6% last month for its best May since 1990 and its strongest monthly performance since November 2023. Meanwhile, the Nasdaq surged nearly 10% as Wall Street dove headfirst back into beaten-down technology stocks. The bulls pressed their advantage to start June, pushing the Nasdaq up 0.7% higher on Monday and 1% through midday trading Tuesday, boosted by strong showings from Nvidia and other tech giants. The bulls are in charge, fueled by tech earnings growth and trade war progress. Now they are attempting to break above a key trading range before they send the market to new all-time highs. It's time to explore how investors can use a Zacks screen to help find some of the best Zacks Rank #1 (Strong Buy) stocks to buy in June and throughout the summer of 2025. Zacks Rank #1 (Strong Buy) stocks outperform the market in good and bad times. However, there are over 200 stocks that earn a Zacks Rank #1 at any given time. Therefore, it's helpful to understand how to apply filters to the Zacks Rank in order to narrow the list down to a more manageable and tradable set of stocks. Clearly, there are only three items on this screen. But together, these three filters can result in some impressive returns. • Zacks Rank equal to 1 Starting with a Zacks Rank #1 is often a strong jumping off point because it boasts an average annual return of roughly 24.4% per year since 1988. • % Change (Q1) Est. over 4 Weeks greater than 0 Positive current quarter estimate revisions over the last four weeks. • % Broker Rating Change over 4 Week equal to Top # 5 Top 5 stocks with the best average broker rating changes over the last four weeks. This strategy comes loaded with the Research Wizard and is called bt_sow_filtered zacks rank5. It can be found in the SoW (Screen of the Week) folder. Here is one of the five stocks that qualified for the Filtered Zacks Rank 5 strategy today… OppFi's (OPFI) works with banks to provide financial products and services for 'everyday Americans' via its tech-enabled digital finance platform. OppFi partners with community banks to offer installment loans to middle-income Americans who are underserved by traditional financial institutions because of low credit scores and more. Image Source: Zacks Investment Research The company's digital OppLoans platform uses AI-driven underwriting to offer transparent, responsible lending with same-day funding. OppFi also supports financial education through partnerships to help customers improve their financial health. OppFi is projected to grow its earnings by 30% this year and 9% next year on 10% and 4%, respective revenue expansion. The financial services firm has crushed our bottom-line estimates by an average of 60% in the trailing four quarters, including a big beat-and-raise Q1 in early May. OppFi's recent upward earnings revisions are part of a much larger uptrend during the past year. Image Source: Zacks Investment Research OPFI stock has soared 300% in the past 12 months to crush its Business Services sector's 13%. Its recent outperformance is part of a 550% two-year run that's taken it above its summer 2021 levels after it went public via a SPAC. Despite the surge, investors can buy OppFi stock 22% below its February peaks while holding its ground above its 2021 IPO levels and its 21-day moving average recently. OppFi also trades at a 60% discount to its sector and 45% below its highs at 9.4X forward 12-month earnings. Get the rest of the stocks on this list and start looking for the newest companies that fit these criteria. It's easy to do. And it could help you find your next big winner. Start screening for these companies today with a free trial to the Research Wizard. You can do it. Click here to sign up for a free trial to the Research Wizard today. Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks' portfolios and strategies are available at: Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OppFi Inc. (OPFI) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
NYSE Arca submits filing for listing of Truth Social Bitcoin ETF
(Reuters) -NYSE Arca on Tuesday submitted a filing to the U.S. markets regulator seeking regulatory approval to list the Truth Social Bitcoin ETF. Spot bitcoin ETFs have gained popularity since their January 2024 debut, drawing billions in inflows as investors seek regulated, liquid exposure to the cryptocurrency. In February, the Trump Media and Technology Group applied to trademark six investment products that track bitcoin and the U.S. manufacturing and energy sectors. U.S. President Donald Trump is the majority owner of TMTG, which runs the social media platform Truth Social. The filing, known as a Form 19b-4, is a requirement that organizations such as stock exchanges submit to the U.S. Securities and Exchange Commission to propose a rule change or to list a new product. It's a key procedural step before an exchange can begin listing and trading a new fund or instrument. The fund will seek to reflect the performance of bitcoin and has been "designed to remove the obstacles represented by the complexities and operational burdens involved in a direct investment in bitcoin." Bitcoin has gained 12.7% so far this year and is trading above $105,000.
Yahoo
37 minutes ago
- Yahoo
Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
FREMONT, Calif., June 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology. Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression. "Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev. Key findings presented: Detection of ctDNA following CRT was independently prognostic of patient outcomes. Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT. Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans. High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death. "We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients." About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit and connect with us on LinkedIn and X (Twitter). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law. Not affiliated with or endorsed by ASCO. View source version on Contacts Investors: Caroline Cornerinvestors@ 415-202-5678 Media Contact pr@
